Mycobacterium genavense Infections in a Tertiary Hospital and Reviewed Cases in Non-HIV Patients

Table 2

Year, samples and microbiological characteristics of the study.

P	Year	Samples studied	ZN	Culture media growth	Samples with growth/DNA	Identification	Susceptibility testing (INH/RIF/STR/ETM/PRZ)
1	2003	Retroperitoneal adenopathy*	+	Bactec 12B and 13A	Retroperitoneal adenopathy	CONV and MB	R/S/S/I/—
2	2007	Blood (2), BAL	−	Bactec 12B and 13A	Blood and BAL	CONV and MB	R/S/S/S/—
3	2007	Retroperitoneal biopsy*, blood, faeces*, sputum	+	Bactec 12B and 13A	Retroperitoneal biopsy, blood, faeces	CONV and MB	R/S/S/S/—
4	2008	Faeces* (3), blood (4), urine (3), BM, sputum	+	Bactec 12B	Faeces	CONV and MB	R/S/S/I/—
5	2010	Faeces* (10), BM*, blood, sputum	+	MGIT and MYCO/F	Faeces, BM, blood	CONV and MB	Not done
6	2010	Faeces* (4), blood, BM*, BAS, spleen*	+	MGIT and MYCO/F	Faeces**, blood, BM**, BAS**, Spleen**	CONV and MB	R/S/S/R/S
7	2011	Faeces* (7) blood, lung biopsy*	+	MYCO/F	Faeces**, blood	CONV and MB	Not done

P: patient; BAL: bronchoalveolar lavage; BM: bone marrow; BAS: bronchoaspirate; ZN: Ziehl-Neelsen staining method; LJ: Löwenstein-Jensen; CONV: convencional; MB: molecular biology; INH: isoniazid; RIF: rifampicin; STR: streptomycin; ETM: ethambutol; PRZ: pyrazinamide; R: resistant; S: susceptible; I: intermediate.
*Samples with acid-fast bacilli.
**Samples in which DNA was detected.